Pharma-Bio Serv Announces Full Year Results - Yahoo Finance
| PBSV Stock | USD 0.55 0.06 9.84% |
Slightly above 62% of Pharma Bio's investor base is looking to short. The analysis of current outlook of investing in Pharma Bio Serv suggests that many traders are alarmed regarding Pharma Bio's prospects. Pharma Bio's investing sentiment can be driven by a variety of factors including economic data, Pharma Bio's earnings reports, geopolitical events, and overall market trends.
Pharma Bio otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Pharma daily returns and investor perception about the current price of Pharma Bio Serv as well as its diversification or hedging effects on your existing portfolios.
Pharma |
Pharma-Bio Serv Announces Full Year Results Yahoo Finance
Read at news.google.com
 |
Pharma Bio Fundamental Analysis
We analyze Pharma Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Bio based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Pharma Bio is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Pharma Bio Serv Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharma Bio otc stock to make a market-neutral strategy. Peer analysis of Pharma Bio could also be used in its relative valuation, which is a method of valuing Pharma Bio by comparing valuation metrics with similar companies.
Peers
Pharma Bio Related Equities
| LIFW | MSP Recovery | 94.01 | ||||
| VHIBF | Vitalhub Corp | 0.97 | ||||
| HCTI | Healthcare Triangle | 0.77 | ||||
| EUDA | EUDA Health | 0.67 | ||||
| HSTM | HealthStream | 0.22 | ||||
| NRC | National Research | 0.00 | ||||
| CERT | Certara | 0.00 | ||||
| DH | Definitive Healthcare | 0.00 | ||||
| OMCL | Omnicell | 0.50 | ||||
| OPRX | OPTIMIZERx Corp | 1.00 | ||||
| CCLD | CareCloud | 4.39 | ||||
| ACON | Aclarion | 5.45 |
Additional Tools for Pharma OTC Stock Analysis
When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.